Form 4 for KLRS Kalaris Therapeutics, Inc.
Accepted 2024-10-23 00:00:00 ET · period of report 2024-10-21 · accession 0000950170-24-116645 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-10-23 | 2024-10-21 | KLRS | Brainard Diana | CEO, Dir | S - Sale | $0.78 | -9,752 | 742.7K | -1% | -$7,607 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-10-21 | S | D | 9,752 | $0.78 | 742,678 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7544 to $0.7964. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |